NASDAQ:ESPR - Esperion Therapeutics Stock Price, Price Target & More

$73.69 -0.47 (-0.63 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$73.69
Today's Range$72.88 - $75.6799
52-Week Range$30.95 - $82.68
Volume293,749 shs
Average Volume536,679 shs
Market Capitalization$1.98 billion
P/E Ratio-10.56
Dividend YieldN/A
Beta2.51

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Debt-to-Equity RatioN/A
Current Ratio6.15%
Quick Ratio6.15%

Price-To-Earnings

Trailing P/E Ratio-10.56
Forward P/E Ratio-13.14
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.34 per share
Price / Book7.89

Profitability

EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-76.84%
Return on Assets-67.42%

Miscellaneous

Employees57
Outstanding Shares26,750,000

How to Become a New Pot Stock Millionaire

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics (NASDAQ:ESPR) issued its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.36. During the same period in the prior year, the firm earned ($1.29) earnings per share. View Esperion Therapeutics' Earnings History.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Esperion Therapeutics.

What price target have analysts set for ESPR?

13 brokers have issued 12 month price objectives for Esperion Therapeutics' shares. Their forecasts range from $64.00 to $153.00. On average, they anticipate Esperion Therapeutics' stock price to reach $96.3077 in the next twelve months. View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
  • 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:
  • Mr. Timothy M. Mayleben, CEO, Pres & Director (Age 57)
  • Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA, Chief Operating Officer and Exec. VP of R&D (Age 65)
  • Dr. Mary P. McGowan M.D., Chief Medical Officer (Age 58)
  • Mr. Richard B. Bartram, CFO, Principal Accounting Officer & Corp. Sec.
  • Ms. Marianne Andreach, Sr. VP of Product Planning

Has Esperion Therapeutics been receiving favorable news coverage?

Media headlines about ESPR stock have been trending positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.29 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include DOMAIN PARTERS VII L P (4.20%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $73.69.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.98 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]


MarketBeat Community Rating for Esperion Therapeutics (ESPR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  656
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $96.3077, suggesting that the stock has a possible upside of 30.69%. The high price target for ESPR is $153.00 and the low price target for ESPR is $64.00. There are currently 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.772.772.852.69
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $96.3077$90.6154$72.8462$58.9167
Price Target Upside: 30.69% upside20.40% upside1.30% upside9.02% upside

Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History

Price Target History for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018Northland SecuritiesBoost Price TargetBuy$100.00 -> $121.00LowView Rating Details
3/27/2018Chardan CapitalBoost Price TargetNeutral -> Neutral$75.00 -> $100.00LowView Rating Details
3/9/2018Deutsche BankBoost Price TargetBuy$100.00LowView Rating Details
3/8/2018JMP SecuritiesBoost Price TargetOutperform$60.00 -> $153.00HighView Rating Details
3/7/2018Stifel NicolausSet Price TargetBuy$105.00HighView Rating Details
2/21/2018UBSSet Price TargetNeutral -> Neutral$88.00 -> $90.00HighView Rating Details
2/21/2018JPMorgan ChaseReiterated RatingNeutral -> Neutral$55.00 -> $65.00HighView Rating Details
2/21/2018Needham & Company LLCReiterated RatingStrong-Buy -> Strong-Buy$81.00 -> $94.00LowView Rating Details
1/22/2018CitigroupDowngradeBuy -> Neutral$77.00 -> $96.00LowView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$103.00LowView Rating Details
1/5/2018Bank of AmericaUpgradeNeutral -> Buy$76.00HighView Rating Details
9/7/2017CowenInitiated CoverageOutperform$64.00LowView Rating Details
8/21/2017Jefferies GroupReiterated RatingBuy$85.00LowView Rating Details
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00HighView Rating Details
8/31/2016BarclaysSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Esperion Therapeutics (NASDAQ:ESPR) Earnings History and Estimates Chart

Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Earnings Estimates

2018 EPS Consensus Estimate: ($5.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.42)($1.42)($1.42)
Q2 20181($1.38)($1.38)($1.38)
Q3 20181($1.35)($1.35)($1.35)
Q4 20181($1.36)($1.36)($1.36)

Esperion Therapeutics (NASDAQ ESPR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($1.56)N/AView Earnings Details
2/20/2018Q4 2017($1.80)($1.44)ViewN/AView Earnings Details
11/7/2017Q3 2017($1.79)($1.86)ViewN/AView Earnings Details
8/8/2017Q2 2017($1.67)($1.92)ViewListenView Earnings Details
5/1/2017Q1 2017($1.4410)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.6050)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.68)($0.64)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.41)($0.34)ViewN/AView Earnings Details
8/12/2013Q2 2013($12.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Esperion Therapeutics (NASDAQ:ESPR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 91.66%
Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ ESPR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Roger S NewtonDirectorSell25,000$72.37$1,809,250.00639,682View SEC Filing  
1/25/2018Nicole VitulloDirectorSell11,674$71.79$838,076.463,177View SEC Filing  
12/6/2017Nicole VitulloDirectorSell9,326$53.85$502,205.102,472View SEC Filing  
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.0010,000View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.005,000View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00600View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.0041,614View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.0010,000View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.0034,614View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.0031,014View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Esperion Therapeutics (NASDAQ ESPR) News Headlines

Source:
DateHeadline
Esperion Therapeutics (ESPR) "Buy" Rating Reiterated at UBSEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 3:36 PM
Esperion Therapeutics (ESPR) PT Raised to $121 at Northland to Reflect High Confidence in P3 OutcomesEsperion Therapeutics (ESPR) PT Raised to $121 at Northland to Reflect High Confidence in P3 Outcomes
www.streetinsider.com - April 20 at 8:51 AM
Northland Securities Boosts Esperion Therapeutics (ESPR) Price Target to $121.00Northland Securities Boosts Esperion Therapeutics (ESPR) Price Target to $121.00
www.americanbankingnews.com - April 19 at 3:36 PM
Esperion Therapeutics (ESPR) Expected to Announce Earnings of -$1.56 Per ShareEsperion Therapeutics (ESPR) Expected to Announce Earnings of -$1.56 Per Share
www.americanbankingnews.com - April 15 at 1:19 AM
Esperion Therapeutics (ESPR) Given Consensus Rating of "Buy" by BrokeragesEsperion Therapeutics (ESPR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 3:31 PM
Esperion Therapeutics (ESPR) Given a $64.00 Price Target at Deutsche BankEsperion Therapeutics (ESPR) Given a $64.00 Price Target at Deutsche Bank
www.americanbankingnews.com - April 11 at 7:18 PM
Esperion Therapeutics (ESPR) Receives "Buy" Rating from Stifel NicolausEsperion Therapeutics (ESPR) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 11 at 5:35 PM
Esperion Therapeutics (ESPR) Earns Buy Rating from Stifel NicolausEsperion Therapeutics (ESPR) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - April 8 at 12:40 AM
Esperion Therapeutics (ESPR) "Buy" Rating Reiterated at Northland SecuritiesEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Northland Securities
www.americanbankingnews.com - April 8 at 12:40 AM
Esperion Therapeutics (ESPR) Rating Increased to Buy at ValuEngineEsperion Therapeutics (ESPR) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Insider Selling: Esperion Therapeutics (ESPR) Director Sells 25,000 Shares of StockInsider Selling: Esperion Therapeutics (ESPR) Director Sells 25,000 Shares of Stock
www.americanbankingnews.com - March 29 at 10:10 PM
Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and ExelixisPre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis
www.prnewswire.com - March 29 at 8:55 AM
Esperion Therapeutics (ESPR) Study 1002-039 Phase 2 Top-Line Results - SlideshowEsperion Therapeutics (ESPR) Study 1002-039 Phase 2 Top-Line Results - Slideshow
seekingalpha.com - March 28 at 5:00 PM
Esperion Therapeutics (ESPR) PT Set at $105.00 by Stifel NicolausEsperion Therapeutics (ESPR) PT Set at $105.00 by Stifel Nicolaus
www.americanbankingnews.com - March 28 at 3:48 PM
Esperion Nets Another Positive Late-Stage Study Under Its BeltEsperion Nets Another Positive Late-Stage Study Under Its Belt
seekingalpha.com - March 28 at 8:57 AM
Results Renew Optimism for Esperion TherapeuticsResults Renew Optimism for Esperion Therapeutics
finance.yahoo.com - March 28 at 8:57 AM
Esperion Therapeutics (ESPR) PT Set at $88.00 by UBSEsperion Therapeutics (ESPR) PT Set at $88.00 by UBS
www.americanbankingnews.com - March 27 at 6:48 PM
Esperion Therapeutics (ESPR) PT Raised to $100.00Esperion Therapeutics (ESPR) PT Raised to $100.00
www.americanbankingnews.com - March 27 at 5:10 PM
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor ...Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor ...
globenewswire.com - March 27 at 4:55 PM
Biohavens IPO Roadshow Fantasy Meets Grimmer RealityBiohaven's IPO Roadshow Fantasy Meets Grimmer Reality
www.bloomberg.com - March 27 at 4:55 PM
Notable Tuesday Option Activity: GPRO, ESPR, INTCNotable Tuesday Option Activity: GPRO, ESPR, INTC
www.nasdaq.com - March 27 at 4:55 PM
Esperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital MarketsEsperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital Markets
www.streetinsider.com - March 27 at 4:55 PM
Will Esperion Therapeutics Inc’s (NASDAQ:ESPR) Earnings Grow In The Years Ahead?Will Esperion Therapeutics Inc’s (NASDAQ:ESPR) Earnings Grow In The Years Ahead?
finance.yahoo.com - March 27 at 4:55 PM
Esperion Therapeutics (ESPR) Stock Rating Lowered by CitigroupEsperion Therapeutics (ESPR) Stock Rating Lowered by Citigroup
www.americanbankingnews.com - March 27 at 11:01 AM
Esperions drug clears study as add-on cholesterol treatmentEsperion's drug clears study as add-on cholesterol treatment
finance.yahoo.com - March 27 at 9:01 AM
Esperion Therapeutics (ESPR) Lifted to Hold at ValuEngineEsperion Therapeutics (ESPR) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM
BidaskClub Downgrades Esperion Therapeutics (ESPR) to HoldBidaskClub Downgrades Esperion Therapeutics (ESPR) to Hold
www.americanbankingnews.com - March 24 at 10:48 AM
Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by BrokeragesEsperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 3:27 PM
-$1.45 Earnings Per Share Expected for Esperion Therapeutics Inc (ESPR) This Quarter-$1.45 Earnings Per Share Expected for Esperion Therapeutics Inc (ESPR) This Quarter
www.americanbankingnews.com - March 11 at 8:35 PM
Head-To-Head Comparison: AEterna Zentaris (AEZS) vs. Esperion Therapeutics (ESPR)Head-To-Head Comparison: AEterna Zentaris (AEZS) vs. Esperion Therapeutics (ESPR)
www.americanbankingnews.com - March 11 at 6:19 PM
Esperion Therapeutics (ESPR) Downgraded to Buy at BidaskClubEsperion Therapeutics (ESPR) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - March 10 at 6:34 PM
Esperion Therapeutics (ESPR) PT Raised to $153.00 at JMP SecuritiesEsperion Therapeutics (ESPR) PT Raised to $153.00 at JMP Securities
www.americanbankingnews.com - March 8 at 10:31 PM
UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% - MarketWatchUPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% - MarketWatch
www.marketwatch.com - March 8 at 8:52 AM
After A Two-Decade Quest, Will Esperions Heart Drug Find A Market?After A Two-Decade Quest, Will Esperion's Heart Drug Find A Market?
finance.yahoo.com - March 7 at 6:01 PM
Has Esperion Therapeutics Inc (NASDAQ:ESPR) Got Enough Cash To Cover Its Short-Term Obligations?Has Esperion Therapeutics Inc (NASDAQ:ESPR) Got Enough Cash To Cover Its Short-Term Obligations?
finance.yahoo.com - March 7 at 6:01 PM
Esperion to Participate in Fireside Chat at March 2018 Investor ConferencesEsperion to Participate in Fireside Chat at March 2018 Investor Conferences
finance.yahoo.com - March 7 at 6:01 PM
Esperion Tanked Despite Strong Cholesterol Drug Trial — Here's WhyEsperion Tanked Despite Strong Cholesterol Drug Trial — Here's Why
finance.yahoo.com - March 7 at 6:01 PM
Esperion Releases Top Line Results For First Pivotal Phase 3 StudyEsperion Releases Top Line Results For First Pivotal Phase 3 Study
finance.yahoo.com - March 7 at 8:50 AM
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic AcidEsperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
finance.yahoo.com - March 7 at 8:50 AM
UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4%UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4%
finance.yahoo.com - March 7 at 8:50 AM
23,333 Shares in Esperion Therapeutics Inc (ESPR) Purchased by Sectoral Asset Management Inc23,333 Shares in Esperion Therapeutics Inc (ESPR) Purchased by Sectoral Asset Management Inc
www.americanbankingnews.com - March 6 at 2:11 PM
Is the Options Market Predicting a Spike in Esperion (ESPR) Stock?Is the Options Market Predicting a Spike in Esperion (ESPR) Stock?
www.zacks.com - March 2 at 8:41 AM
Ascend Capital LLC Purchases Shares of 67,241 Esperion Therapeutics Inc (ESPR)Ascend Capital LLC Purchases Shares of 67,241 Esperion Therapeutics Inc (ESPR)
www.americanbankingnews.com - March 2 at 4:33 AM
Esperion Therapeutics Inc (ESPR) Stake Lessened by EAM Investors LLCEsperion Therapeutics Inc (ESPR) Stake Lessened by EAM Investors LLC
www.americanbankingnews.com - February 27 at 3:00 PM
American Century Companies Inc. Invests $1.60 Million in Esperion Therapeutics Inc (ESPR) StockAmerican Century Companies Inc. Invests $1.60 Million in Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - February 27 at 4:06 AM
Ontario Teachers Pension Plan Board Invests $1.64 Million in Esperion Therapeutics Inc (ESPR) StockOntario Teachers Pension Plan Board Invests $1.64 Million in Esperion Therapeutics Inc (ESPR) Stock
www.americanbankingnews.com - February 26 at 12:28 PM
Esperion Targets $10 a Day for Heart Pill to Undercut RivalsEsperion Targets $10 a Day for Heart Pill to Undercut Rivals
finance.yahoo.com - February 23 at 5:33 PM
Q1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by AnalystQ1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by Analyst
www.americanbankingnews.com - February 23 at 9:59 AM
Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR)Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR)
www.americanbankingnews.com - February 23 at 8:26 AM
 Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS
www.americanbankingnews.com - February 23 at 3:14 AM

SEC Filings

Esperion Therapeutics (NASDAQ:ESPR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.